Comparative Pharmacology
Head-to-head clinical analysis: TAMSULOSIN HYDROCHLORIDE versus UROXATRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAMSULOSIN HYDROCHLORIDE versus UROXATRAL.
TAMSULOSIN HYDROCHLORIDE vs UROXATRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder neck, and prostatic urethra, causing smooth muscle relaxation and improved urine flow.
Selective antagonist of postsynaptic alpha1A-adrenoceptors in the prostate, bladder base, and prostatic urethra, leading to relaxation of smooth muscle and improved urinary flow.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. For patients who fail to respond to 0.4 mg after 2-4 weeks, dose may be increased to 0.8 mg once daily.
10 mg orally once daily, immediately after the same meal each day.
None Documented
None Documented
9-13 hours in healthy subjects, but can increase to 14-16 hours in elderly patients. This supports once-daily dosing, though steady-state is reached by day 5.
The terminal elimination half-life is approximately 5 to 9 hours in healthy young subjects, and 6 to 10 hours in elderly patients. This supports once-daily dosing, with steady state achieved after 3-5 days.
Primarily hepatic metabolism (CYP3A4 and CYP2D6) followed by renal excretion. Approximately 75-90% of a dose is excreted in urine as inactive metabolites, with <10% as unchanged drug. Fecal excretion accounts for 10-15%.
After oral administration, approximately 11% of the dose is excreted unchanged in urine, while 49% is excreted as metabolites in urine and 22% in feces. Overall, renal elimination accounts for about 60% of total clearance.
Category A/B
Category C
Alpha-1 Blocker
Alpha-1 Blocker